YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

Phase 2

Terminated

Conditions: Unresectable Intrahepatic Cholangiocarcinoma

Interventions: Drug: gemcitabine
Drug: Cisplatin
Drug: Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C

First Posted Date: 2016-12-15

Last Posted Date: 2019-12-30

Lead Sponsor: Yale University

Target Recruit Count: 1

Registration Number: NCT02994251

Locations: 🇺🇸
Smilow Cancer Center, New Haven, Connecticut, United States

Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA

Not Applicable

Active, not recruiting

Conditions: Aortic Aneurysm, Thoracoabdominal

Interventions: Device: Physician-modified aortic endograft

First Posted Date: 2016-12-12

Last Posted Date: 2025-01-16

Lead Sponsor: Yale University

Target Recruit Count: 38

Registration Number: NCT02989948

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter

Phase 1

Withdrawn

Conditions: Breast Cancer

Interventions: Radiation: Radioiodide (131I-)

First Posted Date: 2016-12-09

Last Posted Date: 2018-08-22

Lead Sponsor: Yale University

Registration Number: NCT02988648

Locations: 🇺🇸
Smilow Cancer Center, New Haven, Connecticut, United States

Psilocybin for the Treatment of Cluster Headache

Phase 1

Completed

Conditions: Cluster Headache

Interventions: Drug: 0.0143 mg/kg Psilocybin or 1 mg Psilocybin
Drug: 0.143 mg/kg Psilocybin or 10 mg Psilocybin
Drug: Placebo

First Posted Date: 2016-12-05

Last Posted Date: 2023-12-15

Lead Sponsor: Yale University

Target Recruit Count: 25

Registration Number: NCT02981173

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2

Active, not recruiting

Conditions: Squamous Cell Cancers of the Head and Neck

Interventions: Drug: cetuximab
Drug: afatinib

First Posted Date: 2016-12-02

Last Posted Date: 2025-05-07

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT02979977

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Betadine Pleurodesis Via Tunneled Pleural Catheters

Phase 4

Withdrawn

Conditions: Pleurodesis
Pleural Effusions, Chronic
Pleural Effusion
Malignant Pleural Effusion
Pleural Effusion Due to Congestive Heart Failure
Pleural Effusion in Conditions Classified Elsewhere

Interventions: Drug: Povidone-Iodine

First Posted Date: 2016-11-29

Last Posted Date: 2019-01-11

Lead Sponsor: Yale University

Registration Number: NCT02975921

A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Behavioral: Teens.Connect

First Posted Date: 2016-11-22

Last Posted Date: 2019-04-02

Lead Sponsor: Yale University

Target Recruit Count: 29

Registration Number: NCT02970656

Locations: 🇺🇸
Yale School of Nursing, West Haven, Connecticut, United States

Hand Grip Strength as a Marker of Frailty in Surgical Patients

Terminated

Conditions: Frailty

Interventions: Device: Obtain grip strength from a standardized gripometer

First Posted Date: 2016-11-17

Last Posted Date: 2020-02-10

Lead Sponsor: Yale University

Target Recruit Count: 52

Registration Number: NCT02966470

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

PRIME vs Usual Care for Clinical High Risk

Not Applicable

Completed

Conditions: Clinical High Risk Syndrome for Psychosis

Interventions: Other: PRIME care
Other: Usual care

First Posted Date: 2016-11-09

Last Posted Date: 2019-05-28

Lead Sponsor: Yale University

Target Recruit Count: 16

Registration Number: NCT02960451

Locations: 🇺🇸
Prevention through Risk Identification Management and Education (PRIME) Clinic, New Haven, Connecticut, United States

Saracatinib and Alcohol Drinking

Phase 2

Completed

Conditions: Alcohol Drinking

Interventions: Drug: Placebos
Drug: Saracatinib

First Posted Date: 2016-11-04

Last Posted Date: 2020-11-13

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT02955186

Locations: 🇺🇸
CMHC, Substance Abuse Center, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy